Risk of second primary cancers in cancer patients treated with cisplatin: a systematic review and meta-analysis of randomized studies

Overview of attention for article published in BMC Cancer, December 2017

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (94th percentile)
High Attention Score compared to outputs of the same age and source (96th percentile)

So far, Altmetric has seen 52 X posts from 51 X users, with an upper bound of 366,498 followers.

RT @theliverdr: Dear Hakeem, Since u r not a real doc U can't know real medical science Allow me Cisplatin is ANTI-cancer Chlornaphazine -…

RT @theliverdr: Dear Hakeem, Since u r not a real doc U can't know real medical science Allow me Cisplatin is ANTI-cancer Chlornaphazine -…

RT @theliverdr: Dear Hakeem, Since u r not a real doc U can't know real medical science Allow me Cisplatin is ANTI-cancer Chlornaphazine -…

RT @theliverdr: Dear Hakeem, Since u r not a real doc U can't know real medical science Allow me Cisplatin is ANTI-cancer Chlornaphazine -…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 48 additional X posts.